integrin binding peptide

Integrin Binding Peptide, derived from fibronectin, holds the potential as an essential component for preparing PEG hydrogels.

Integrin Binding Peptide acetate is a synthetic peptide derived from the fibronectin protein that selectively binds integrins. Integrin Binding Peptide acetate can be employed as a functional biomolecule in the preparation of PEG-based hydrogels, providing a biologically active interface for cell adhesion, migration, and mechanotransduction studies in tissue engineering and regenerative medicine.

Hexapeptide-10 Acetate (Hexapeptide-10 Acetate) is a synthetic peptide. It increases the synthesis of laminin V and α6-integrin to promote cell binding, with extraordinary visible skin restructuring and firming abilities.

ATN-161 is an integrin α5β1 binding peptide and antagonist that inhibits VEGF-induced hCECs migration and angiogenesis. ATN-161 also suppresses spike protein interaction with integrin α5β1 and may be employed against SARS-CoV-2 infection.

GRGDSPK TFA (EMD 56574 TFA) is a peptide containing the Arg-Gly-Asp (RGD) sequence, serving as a competitive and reversible inhibitor of integrin-fibronectin binding. This compound is utilized in research to elucidate integrins' involvement in bone formation and resorption [1] [2].

RGD-4C, an arginine-glycine-aspartic acid peptide (ACDCRGDCFC), exhibits integrin binding activity. The primary integrin recognition site in extracellular matrix proteins, the Arg-Gly-Asp (RGD) sequence, allows peptides with this sequence to mimic matrix proteins' recognition specificity. As an αv-integrin ligand, RGD-4C can be conjugated with bioactive molecules to demonstrate antitumor effects in animal models [1] [2] [3].

Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide and synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin on Caco-2 cells [1].

Batifiban TFA, a cyclic peptide and antagonist of the platelet glycoprotein GPⅡb/Ⅲa, inhibits platelet aggregation by blocking the binding of circulating vitronectin to integrin ανβ3 [1].

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1/2.

Hexapeptide-10 is a synthetic peptide. It increases the synthesis of laminin V and α6-integrin to promote cell binding, with extraordinary visible skin restructuring and firming abilities.

VSLRGDTRG acetate is a synthetic peptide of the RGD motif from cadherin17 (CDH17), capable of binding to α2β1 integrin and activating its signaling pathways. It facilitates the high-affinity conformational change of β1 integrin via the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby promoting tumor proliferation and metastasis. VSLRGDTRG acetate is applicable in research on cancers expressing CDH17, such as colon and pancreatic cancers.

LDV-FITC TFA is a fluorescent peptide, specifically an FITC-conjugated LDV peptide. This compound binds to the α4β1 integrin with high affinity, displaying a Kd of 0.3 nM in the presence of Mn2+ and 12 nM in its absence, when binding to U937 cells. LDV-FITC TFA is useful for assessing α4β1 integrin affinity.

GFOGER peptide is an integrin ligand peptide for α2β1, α1β1, and α11β1. It is recognized through direct interaction with integrins at its Glu and Arg residues, particularly binding to Glu via the metal ion-dependent adhesion site (MIDAS).